SUFENTANIL CITRATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for sufentanil citrate and what is the scope of freedom to operate?
Sufentanil citrate
is the generic ingredient in three branded drugs marketed by Rising, Hikma, Hospira, Watson Labs, and Vertical Pharms, and is included in five NDAs. There are twenty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.Sufentanil citrate has one hundred and five patent family members in twenty countries.
There are five drug master file entries for sufentanil citrate. Three suppliers are listed for this compound.
Summary for SUFENTANIL CITRATE
International Patents: | 105 |
US Patents: | 21 |
Tradenames: | 3 |
Applicants: | 5 |
NDAs: | 5 |
Drug Master File Entries: | 5 |
Finished Product Suppliers / Packagers: | 3 |
Raw Ingredient (Bulk) Api Vendors: | 31 |
Clinical Trials: | 7 |
Patent Applications: | 1,067 |
What excipients (inactive ingredients) are in SUFENTANIL CITRATE? | SUFENTANIL CITRATE excipients list |
DailyMed Link: | SUFENTANIL CITRATE at DailyMed |
Recent Clinical Trials for SUFENTANIL CITRATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Brugmann University Hospital | Phase 3 |
Jiangang Song | N/A |
West China Hospital | Phase 4 |
Pharmacology for SUFENTANIL CITRATE
Drug Class | Opioid Agonist |
Mechanism of Action | Full Opioid Agonists |
Medical Subject Heading (MeSH) Categories for SUFENTANIL CITRATE
Anatomical Therapeutic Chemical (ATC) Classes for SUFENTANIL CITRATE
US Patents and Regulatory Information for SUFENTANIL CITRATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertical Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Vertical Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Vertical Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Vertical Pharms | DSUVIA | sufentanil citrate | TABLET;SUBLINGUAL | 209128-001 | Nov 2, 2018 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Hikma | SUFENTANIL CITRATE | sufentanil citrate | INJECTABLE;INJECTION | 074413-001 | Dec 15, 1995 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for SUFENTANIL CITRATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Rising | SUFENTA PRESERVATIVE FREE | sufentanil citrate | INJECTABLE;INJECTION | 019050-001 | May 4, 1984 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for SUFENTANIL CITRATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 101445891 | ⤷ Sign Up | |
European Patent Office | 2114383 | FORMES DOSIFIÉES DE PETIT VOLUME DE MÉDICAMENT CONTENANT DU SUFENTANIL S'ADMINISTRANT PAR VOIE TRANS-MUQUEUSE ORALE POUR LE TRAITEMENT DE LA DOULEUR (SMALL VOLUME ORAL TRANSMUCOSAL DOSAGE FORMS CONTAINING SUFENTANIL FOR TREATMENT OF PAIN) | ⤷ Sign Up |
Portugal | 3072504 | ⤷ Sign Up | |
Spain | 2348688 | ⤷ Sign Up | |
Canada | 2673856 | FORMES DOSIFIEES DE PETIT VOLUME DE MEDICAMENT CONTENANT DU SUFENTANIL S'ADMINISTRANT PAR VOIE TRANS-MUQUEUSE ORALE POUR LE TRAITEMENT DE LA DOULEUR (SMALL VOLUME ORAL TRANSMUCOSAL DOSAGE FORMS CONTAINING SUFENTANIL FOR TREATMENT OF PAIN) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for SUFENTANIL CITRATE
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2114383 | SPC/GB16/004 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: SUFENTANIL; REGISTERED: UK EU/1/15/1042 20150922 |
2114383 | CA 2016 00007 | Denmark | ⤷ Sign Up | PRODUCT NAME: SUFENTANIL, HERUNDER SUFENTANIL SOM CITRAT; REG. NO/DATE: EU/1/15/1042/001-006 20150922 |
2114383 | CR 2016 00007 | Denmark | ⤷ Sign Up | PRODUCT NAME: SUFENTANIL; REG. NO/DATE: EU/1/15/1042/001-006 20150922 |
2114383 | 122016000023 | Germany | ⤷ Sign Up | PRODUCT NAME: SUFENTANIL, WAHLWEISE IN FORM VON SUFENTANILCITRAT; REGISTRATION NO/DATE: EU/1/15/1042 20150918 |
2114383 | 300797 | Netherlands | ⤷ Sign Up | PRODUCT NAME: SUFENTANIL, DESGEWENST IN DE VORM VAN SUFENTANILCITRAAT; REGISTRATION NO/DATE: EU/1/15/1042 20150922 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.